HEART SENTRY - By lexingtonBioSciences.com

Lexington Bio Sciences new :Heart Sentry"!

Wednesday, January 9, 2019

SmallCaps and MicroCap Stocks catch Investor interest in first week of 2019

In the interest of full disclosure, we bought these SmallCap Stocks in late 2018.

Several of these small Technology Stocks are up over 50% in the first week of trading in 2019.

(Note: We place no more than 10% of our RETIRE.FUND portfolio into Smallcap Stocks!)
- - - - - - - - - - - - - -

Intrinsyc Technologies Inc.

Small-cap leader in the IOT/AI space working with Qualcomm and other Tech Co's
Growing it's customer base, growing it's book, has positive cash flow and we believe
may be a Takeover Target in 2019!

Intrinsyc Technologies Corporation is a product development company, publicly traded (TSX: ITC) and headquartered in Vancouver, BC, Canada.

Intrinsyc offers a portfolio of embedded computing modules based on Snapdragon™ technology from Qualcomm® Technologies, Inc, and i.MX processors from NXP Semiconductors N.V. These production-ready computing solutions provide the benefit of rapid time to market, while still offering the flexibility of a semi-custom design.

Currently manufacturing their own extensive list of IOT products with many buying customers.
They are already a profitable company, with no where to go but up!

- - - - - - - - - - - - - - - - - - - - - - - - - - -

Lexington Bio Sciences

Holds patents on it's revolutionary "Heart Sentry" device which was developed over 15 yrs of research and is considered 500 times more accurate in determining the prevalence of Heart Disease (early detection) than standard ultra sound and blood pressure tests.

Currently in field testing (with great results) in two different Hospitals in the USA and Canada, Heart Sentry is now on fast track for FDA approval in 2019!

- - - - - - - - - - - - - - - - - - - - - -

DMG Blockchain Solutions Inc.

This Small Cap, Crypto/Blockchain enterprise is into the "Picks and shovels" of Blockchain's revolution, and in late 2018, went live with it's plant in Northern BC, Canada which is completely supplied with it's own, Environmentally friendly, locally developed power system.

This dynamic small Tech company is helping build the future, one blockchain at a time!

What DMG Does for it's clients:


Known as MaaS – Mining as a Service Management of Bitcoin mining facilities on behalf of third parties globally.


Development of Blockchain platforms for Supply Chain, IoT and Payments


Certified Fraud Examiners (CFEs) work in partnership with Blockchain analytic software companies

 - - - - - - - - - - - - - - - - - - - - - - - - - - -

NEO Lithium inc

This company may still be small, but the lithium property is huge!

Their "3Q" project , located on the Puna Plateau, in the Lithium Triangle is one of the purest lithium deposit on the planet, it's huge, and it sits in the Atacama Desert of Argentina, between the Big Dogs of the Lithium revolution!

They have fast tracked the project and should be in production in 24 months.

The size of the deposit, the purity of the deposit and the location of the deposit, lead us to believe that NEO is a prime takeover target

Also - Argentina is firing on all lithium cylinders, to pass Chile as the Lithium capital of the world!
- - - - - - - - - - - - - - - - - - - - - -

Friends, don't count out small and micro cap stocks this year.

Especially those small Tech Stocks that both investors, and large tech companies, are paying attention to!


Sunday, December 30, 2018

Crypto Investors have been scooping up Crypto web Domains

Recently, the web Domain ETH.com sold for a cool $2,000,000

Domain Investors have been scooping up Crypto Domains as the Blockchain revolution continues to grow. No one really knows where that growth, with it's obvious ups and downs, will take us, however Blockchain Technology is considered by many experts and investors, to be the transaction Tech of the future!

Blockchains like Bitcoin, Ethereum, Ripple, Neo and Nem are leaders in this new technology!

To that end, DomainNames.Money is offering for sale or lease, a number of Crypto/Money Domains!

They include:


To see the details for one of these premium Domain Names, just click on the word and you will be brought to the page where you can either buy, make a bid, or lease arrangement!

Your CRYPTO identity may depend on it!

Wednesday, August 29, 2018

Retire Fund Web Domain Package

Retire Fund Web Domain

On Sale!

You may also consider these RetireFund Domains on auction:


To buy any of these premium web addresses just click on the domain of your choice to see the details:



These two Domains were sold for these prices previously:

RETIRE.COM  $2,000,000
FUND.COM    $10,000,000

NOW!  Your company can own 6
Retire Fund Domains!!!

RetireFund - What are your clients doing?
                        "AFTER WORK"!

Note: The sale and Escrow will be handled by reliable third party broker Epik.com

Wednesday, July 25, 2018

Lexington Biosciences Receives HeartSentry USPTO Patent Approval!

VANCOUVER, BC – July 25, 2018) – Lexington Biosciences, Inc. (Toronto TSE: LNB) (OTCQB: LXGTF) is pleased to announce the issuance of U.S. Patent No. 10,028,664, which covers aspects of its HeartSentry device.

“Today’s news is a big deal for Lexington,” says Company CEO, Eric Willis. “The US Patent Office and our legal team did an extraordinary job in arriving at this approval so quickly. The fact that all key claims were reviewed and approved without significant amendment speaks volumes to the veracity of our research and the clearly defined parameters of the operating methodology. We also have numerous patents pending on individual aspects of the science, both domestically and overseas, but this particular patent approval should pave the way for subsequent approvals in other global jurisdictions.”

HeartSentry was designed by Lexington’s lead researcher, Chief
Scientific Advisor Jonathan S. Maltz, Ph.D., as a diagnostic device that provides a new approach to non-invasive measurement and monitoring of cardiovascular health. 

 The device assesses the function of a patient’s vascular endothelium, the vital innermost lining of the cardiovascular system. The Company designed HeartSentry to be highly portable, accurate, quick, and cost-effective, with the intent to position it to become the standard of care for cardiologists, general practitioners, and ultimately for patients as a first-line evaluation of cardiovascular health.

The public is invited to follow us on Facebook, Twitter and LinkedIn. To receive our newsletter and news alerts direct to your inbox, you can signup at any time on any of the signup opportunities or “contact” page of our website.

To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead.

About Lexington Biosciences, Inc. (CSE: LNB / OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of the cardiovascular system.  Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician.

HeartSentry core technology was developed at the Lawrence Berkeley National Laboratory over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.  Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.

On Behalf of the Board,
“Eric Willis”
Eric Willis
CEO  Director

Lexington Biosciences, Inc.
+1 (800) 320-2640

Thursday, June 21, 2018

Trade Wars never end well - History shows us why!

History's Not on the Market's Side in a Trade War - Article at Bloomberg


The first shots of a global trade war were fired on Friday as U.S. President Donald Trump announced a 25 percent levy on $50 billion of imports from China. The tariffs focus on “industrially significant technology,” and intend to hurt China for alleged theft of intellectual property rights. China responded within hours with a detailed list of imports from the U.S. valued at $50 billion that it would impose a similar 25 percent tax on...


Trumps Trade War makes no sense....

Washington Post

A Trade War with China damages both sides...

New York Times Article... 

Markets begin to take Trade War Seriously...

Wall Street Journal 

Trump's Trade War will hurt Economy....

Why Donald Trump's trade wars are so risky now...